Haemonetics acquires Vivasure to expand large-bore vessel closure solutions

Haemonetics has announced the acquisition of Vivasure Medical Limited, a Galway-based medical technology company focused on next-generation solutions for percutaneous vessel closure. The move strengthens Haemonetics’ position in interventional technologies, particularly as large-bore access becomes more common in structural heart and endovascular procedures.

What Vivasure brings to the table

At the heart of the acquisition is Vivasure’s PerQseal® Elite system, a sutureless and fully absorbable solution designed to close large-bore arteriotomies and venotomies of up to 26 F. The system uses a proprietary bioabsorbable patch to seal the vessel from the inside, removing the need for pre-close techniques and simplifying workflow for clinicians.

Clinical results and regulatory progress

PerQseal Elite is supported by data from the ELITE arterial study, a prospective, multi-centre trial that demonstrated ease of use, immediate median time to hemostasis, and no major complications at 30-day follow-up. In 2025, Vivasure submitted a Premarket Approval application to the U.S. FDA for the arterial indication. In Europe, the system has already received CE Mark approval for both arterial and venous use.

Strengthening Haemonetics’ closure portfolio

With this acquisition, Haemonetics expands its range of vessel closure devices, adding technology tailored for large-bore access. According to Ken Crowley, Vice President and General Manager, Interventional Technologies at Haemonetics, PerQseal Elite complements the company’s existing offerings and supports its focus on fast-growing structural heart and endovascular procedures.

“Acquiring Vivasure expands Haemonetics’ complete range of closure devices with new and clinically differentiated technology to bolster our presence in the large-bore closure market and our impact in fast-growing structural heart and endovascular procedures,” said Ken Crowley, Vice President & General Manager, Interventional Technologies at Haemonetics.

“With strong clinical performance and safety data, PerQseal Elite positions us for increased leadership in advanced closure, as we leverage our commercial scale and operational synergies to deliver increased value to physicians and hospitals.”

Financial terms of the deal

The transaction includes an upfront cash payment of €100 million, or approximately €52 million net after accounting for previous investments and loans, along with up to €85 million in additional contingent consideration linked to sales growth and key milestones. Haemonetics financed the acquisition using available cash on hand.

A new chapter for Vivasure

For Vivasure, joining Haemonetics marks an important step in expanding the reach of its technology.

“We’re extremely proud of the progress made in advancing closure technology, and grateful to the clinicians, employees, board members, investors and government bodies who supported Vivasure’s mission,” said Andrew Glass, Chief Executive Officer of Vivasure Medical Limited.

“Joining Haemonetics provides the global scale and resources to accelerate the availability of PerQseal Elite and bring its clinical benefits to more physicians and patients worldwide.”

Looking ahead

As minimally invasive procedures continue to evolve, vessel closure plays an increasingly important role in procedural success and patient recovery. By bringing Vivasure into its portfolio, Haemonetics signals a clear focus on advancing closure solutions that support clinicians and improve outcomes across interventional care.

Source:

Vivasure Medical

Interested in the trends in interventional care and MedTech innovation globally?

Join industry leaders, innovators, investors, and healthcare decision-makers at MedTech World Middle East | Dubai 2026, where discussions around technology adoption, partnerships, and market direction take centre stage.